Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

Multiple myeloma is a relatively uncommon cancer of plasma cells, where excessive proliferation of these malignant cells within the bone marrow leads to abnormal antibody production. The disease ...

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma from precursor disease, which may help better identify ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens ...